# A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy

> **NCT07642050** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Biohaven Therapeutics Ltd.** · enrollment: 420 (estimated)

## Conditions studied

- IgA Nephropathy

## Interventions

- **DRUG:** BHV-1400
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07642050
- **Lead sponsor:** Biohaven Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-09
- **Final completion:** 2029-10
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07642050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07642050, "A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07642050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*